Use of cd25 binding molecules in steroid-resistant patients

Details Use of cd25 binding molecules in steroid-resistant patients Use of cd25 binding molecules in steroid-resistant patients

C - Chemistry, Metallurgy

07

K

C07K 16/28 (2006.01) A61K 31/704 (2006.01) A61K 39/00 (2006.01) A61K 39/395 (2006.01)

Patent

CA 2443405

A method for the treatment of a disease selected from the group consisting of autoimmune hepatitis, eczema, vasculitis, temporal arteritis, sarcoid and Crohn's disease, in a steroid-resistant or steroid-sensitive patient, comprising administering to the patient an effective amount of a CD25 binding molecule.

L'invention concerne une méthode de traitement d'une maladie sélectionnée dans le groupe constitué par l'hépatite autoimmune, l'eczéma, la vascularite, la maladie de Horton (artérite temporale), les sarcoïdes et la maladie de Crohn, chez un patient résistant aux stéroïdes ou sensible aux stéroïdes, la méthode consistant à administrer au patient une quantité efficace d'une molécule de liaison CD25.

Affiliated with

Also associated with

Rating

Use of cd25 binding molecules in steroid-resistant patients does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of cd25 binding molecules in steroid-resistant patients, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of cd25 binding molecules in steroid-resistant patients will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1760037